Evidence map›Paper›PMID 28955697›Full record

ReviewVascular specialist international2017

Cilostazol for Secondary Prevention of Stroke: Should the Guidelines Perhaps Be Extended?

George Galyfos, Argyri Sianou

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vascular specialist international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Pharmacodynamic of cilostazol for anti-altitude hypoxia.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022
    Article
  4. Treatment Approaches to Lacunar Stroke.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

George GalyfosDivision of Vascular Surgery, Department of Propaedeutic Surgery, University of Athens Medical School, Hippocration Hospital, Athens, Greece.
Argyri SianouDepartment of Microbiology, University of Athens Medical School, Areteion Hospital, Athens, Greece.
Aretaeio Hospital · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cilostazol belongs to the new generation antiplatelet agents that have been introduced and studied regarding a potential role in cardiovascular disease prevention or treatment. Although data on peripheral artery disease are sufficient, and the drug has been recommended as first line treatment for intermittent claudication, it has not been approved nor recommended as far as cerebrovascular events are concerned. However, a great volume of randomized as well as pooled data has been published during the last years. Therefore, this review aims to describe the basic mechanisms of cilostazol's action as well as to present all recent clinical data in order to conclude on whether official guidelines should be extended.

Indexed as

GuidelineSecondary preventionStroke

Identifiers

PMID28955697
PMCPMC5614376
OpenAlexW2756363410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.